Various clinical trials have evaluated the clinical value of an initial dose intensification of imatinib in CML-CP patients (an overview of the most important response rates is given in Table 1).

Inhibikase Therapeutics ( (IKT) ) has provided an announcement. Inhibikase Therapeutics, Inc. released a new presentation on ...

bDepartment of Applied Science at the Swiss Federal Institute of Technology, Zurich, Switzerland Treatment options for patients with chronic myeloid leukaemia (CML) and other types of leukaemia ...

Most employers have little idea what the pharmacy benefit managers they hire do with the money they exchange for the ...

Blood cancer is not always fatal and advancements in treatment offer significant hope. Misconceptions exist, such as it being ...

Background and Objective: Imatinib mesylate is the first effective therapy for advanced unresectable gastrointestinal stromal tumours (GIST). Adoption of this therapy in clinical practice is ...

Critics say big pharmacy benefit managers — which are parts of conglomerates that include pharmacies, providers and insurers ...

Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225] Draft guidance Technology appraisal ...

Most patients diagnosed with chronic-phase chronic myeloid leukemia (CP-CML) who achieved a deep molecular response on ...

Kura Oncology Inc (KURA) showcases promising developments in its oncology pipeline while navigating increased R&D expenses and financial pressures.

Researchers are advising against the interruption of treatment with Gleevec among patients with advanced gastrointestinal ...

A key gene that could enhance the treatment success rates of chronic myeloid leukemia (CML) has been discovered by ...